Skip to main content
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report
August 17, 2022
Participation terms in the Combined General Meeting
August 8, 2022
MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report
July 29, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
July 27, 2022
MedinCell announces its full year financial results April 2021 – March 2022
June 14, 2022
Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022
June 7, 2022
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer
May 9, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM
May 3, 2022
